• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Philips completes $2.8B BioTelemetry acquisition

Philips completes $2.8B BioTelemetry acquisition

February 9, 2021 By Sean Whooley

Royal Philips (NYSE:PHG) announced today that it successfully completed its acquisition of all outstanding shares of BioTelemetry (NSDQ:BEAT).

Amsterdam-based Philips announced in December 2020 that it agreed to acquire the shares of BioTelemetry at a per-share price of $72, totaling approximately $2.8 billion. At 12 a.m. ET today, the offer expired as scheduled and was not extended as Philips expects to complete the acquisition later today through a merger, according to a news release.

As of the expiration of the offer, a total of more than 27 million shares (representing almost 79% of BioTelemetry’s outstanding shares) had been tendered into and not validly withdrawn. Additionally, the companies were advised that another 1.57 million shares were tendered by notice of guaranteed delivery. All shares that were validly tendered and not properly withdrawn were accepted for payment and Philips will pay for all such tendered shares in accordance with the terms of the offer.

Through the merger, BioTelemetry is slated to become a wholly-owned subsidiary of Philips, with the BEAT ticker set to no longer be listed on the NASDAQ market.

BioTelemetry develops diagnostics and monitors for heart rhythm disorders, including wearable heart monitors that detect and transmit abnormal heart rhythms wirelessly, along with AI-based data analytics and services. The previous announcement of the transaction said that BioTelemetry and its approximately 1,900 employees will join Philips’ connected care business segment.

Philips anticipated in December that the acquisition will be sales growth and EBITA margin accretive in 2021, with the BioTelemetry slated to grow double-digits and improve the company’s adjusted EBITA margin to more than 20% by 2025.

Filed Under: Business/Financial News, Cardiovascular, Featured, Health Technology, Mergers & Acquisitions, Patient Monitoring, Software / IT Tagged With: BioTelemetry, Philips

More recent news

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy